Dengfeng Dou

Dr. Dengfeng Dou

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2023 in ACS Chemical Biology
Verified
Journal Article
Open access
QCQiuxia Chen
Qiuxia Chen
CLChuan Liu
Chuan Liu
WWWei Wang
Wei Wang
XMXiaoyun Meng
Xiaoyun Meng
XCXuemin Cheng
Xuemin Cheng
DDDengfeng Dou
Dengfeng Dou
The proteolysis targeting chimera (PROTAC) strategy results in the down-regulation of unwanted protein(s) for disease treatment. In the PROTAC process, a heterobifunctional degrader forms a ternary complex with a target protein of interest (POI) and an E3 ligase, which results in ubiquitination and proteasomal degradation of the POI. While ternary complex formation is a key attribute of PROTAC degraders, modification of the PROTAC molecule to optimize ternary complex formation and protein degradation can be a labor-intensive and tedious process. In this study, we take advantage of DNA-encoded library (DEL) technology to efficiently synthesize a vast number of possible PROTAC molecules and describe a parallel screening approach that utilizes DNA barcodes as reporters of ternary complex formation and cooperative binding. We use a designed PROTAC DEL against BRD4 and CRBN to describe a dual protein affinity selection method and the direct discovery of novel, potent BRD4 PROTACs that importantly demonstrate clear SAR. Such an approach evaluates all the potential PROTACs simultaneously, avoids the interference of PROTAC solubility and permeability, and uses POI and E3 ligase proteins in an efficient manner.

14 March 2022 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
QCQiuxia Chen
Qiuxia Chen
YLYou Li
You Li
CLChunrong Lin
Chunrong Lin
LCLiu Chen
Liu Chen
HLHao Luo
Hao Luo
DDDengfeng Dou
Dengfeng Dou
DNA-encoded library (DEL) technology is a powerful tool for small molecule identification in drug discovery, yet the reported DEL selection strategies were applied primarily on protein targets in either purified form or in cellular context. To expand the application of this technology, we employed DEL selection on an RNA target HIV-1 TAR (trans-acting responsive region), but found that the majority of signals were resulted from false positive DNA–RNA binding. We thus developed an optimized selection strategy utilizing RNA patches and competitive elution to minimize unwanted DNA binding, followed by k-mer analysis and motif search to differentiate false positive signal. This optimized strategy resulted in a very clean background in a DEL selection against Escherichia coli FMN Riboswitch, and the enriched compounds were determined with double digit nanomolar binding affinity, as well as similar potency in functional FMN competition assay. These results demonstrated the feasibility of small molecule identification against RNA targets using DEL selection. The developed experimental and computational strategy provided a promising opportunity for RNA ligand screening and expanded the application of DEL selection to a much wider context in drug discovery.

24 August 2021 in ACS Omega
Verified
Journal Article
Open access
YYYang Yu
Yang Yu
TXTingyang Xu
Tingyang Xu
JLJiawen Li
Jiawen Li
YQYaping Qiu
Yaping Qiu
YRYu Rong
Yu Rong
JHJunzhou Huang
Junzhou Huang
We have developed a graph-based Variational Autoencoder with Gaussian Mixture hidden space (GraphGMVAE), a deep learning approach for controllable magnitude of scaffold hopping in generative chemistry. It can effectively and accurately generate molecules from a given reference compound, with excellent scaffold novelty against known molecules in the literature or patents (97.9% are novel scaffolds). Moreover, a pipeline for prioritizing the generated compounds was also proposed to narrow down our validation focus. In this work, GraphGMVAE was validated by rapidly hopping the scaffold from FDA-approved upadacitinib, which is an inhibitor of human Janus kinase 1 (JAK1), to generate more potent molecules with novel chemical scaffolds. Seven compounds were synthesized and tested to be active in biochemical assays. The most potent molecule has 5.0 nM activity against JAK1 kinase, which shows that the GraphGMVAE model can design molecules like how a human expert does but with high efficiency and accuracy.

18 April 2025 in ACS Chemical Biology
Verified
Journal Article
Closed access
XLXiaomei Li
Xiaomei Li
QWQingyang Wang
Qingyang Wang
AGAnping Guo
Anping Guo
YQYaping Qiu
Yaping Qiu
QCQiuxia Chen
Qiuxia Chen
DDDengfeng Dou
Dengfeng Dou

5 March 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
WHWei-jun Huang
Wei-jun Huang
YYYasufumi Yamamoto
Yasufumi Yamamoto
YLYi Li
Yi Li
DDDengfeng Dou
Dengfeng Dou
KAKevin R. Alliston
Kevin R. Alliston
WGWilliam C. Groutas
William C. Groutas
The mechanism of action of a general class of mechanism-based inhibitors of serine proteases, including human neutrophil elastase (HNE), has been elucidated by determining the X-ray crystal structure of an enzyme–inhibitor complex. The captured intermediate indicates that processing of inhibitor by the enzyme generates an N-sulfonyl imine functionality that is tethered to Ser195, in accordance with the postulated mechanism of action of this class of inhibitors. The identity of the HNE-N-sulfonyl imine species was further corroborated using electrospray ionization mass spectrometry.

9 April 2025 in ACS Chemical Biology
Verified
Journal Article
Closed access
YCYalong Cheng
Yalong Cheng
LCLongzhi Cao
Longzhi Cao
PLPanrui Lu
Panrui Lu
LXLei Xue
Lei Xue
XLXiaomei Li
Xiaomei Li
THTing Han
Ting Han